Undoubtedly, interest in this therapeutic approach has been renewed with the demonstration that very low doses of the CD19/CD3 BiTE antibody construct, blinatumomab, can eliminate target cells in patients with non-Hodgkin’s lymphomas [22]. Here, CEP70 is linked to non-Hodgkin lymphoma.